stars 1 stars 2 stars 3

Aferrix is an innovative leader in development and applications of novel tools for early diagnosis and monitoring of toxic iron in the serum. The company has developed several methods that quantify different forms of toxic iron in the serum, which are not detected by conventional tests. Aferrix offers iron testing services and kits for research and treatment centers that specialize in iron over load diseases (Thalassemia, Hemochromatosis, Myelodysplastic syndrome) and to pharmaceutical companies that are developing iron chelators. The company was founded by Prof. Zvi Ioav Cabantchik, Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem, Israel.

Aferrix Questions

The Aferrix annual revenue was $4 million in 2026.

Aferrix is based in Tel Aviv, Tel Aviv.

The NAICS codes for Aferrix are [5417, 54, 541713, 541, 54171].

The SIC codes for Aferrix are [87, 873].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users